A Phase I, Randomized, Placebo-Controlled, Double-Blind (Sponsor Unblind), Three Part Study to Evaluate the Safety, Tolerability, Preliminary PK and PD of Single and Repeat Oral Doses of GSK3008356 in Healthy Subjects and Obese Subjects
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2017
At a glance
- Drugs GSK 3008356 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 12 Jul 2017 Status changed from recruiting to completed.
- 18 May 2017 Planned End Date changed from 1 May 2017 to 1 Jun 2017.
- 18 May 2017 Planned primary completion date changed from 1 May 2017 to 1 Jun 2017.